CHO Pharma

CHO Pharma Current Liabilities

The Current Liabilities of CHO Pharma (6586.TWO) as of Nov 2, 2026 is 877,000.00 TWD. In the previous year, Current Liabilities was 110.87 M TWD — a change of -99.21% (lower).

Current Liabilities

877,000.00TWD

YoY

-99.21%

Last updated:

Current Liabilities of CHO Pharma is 2025 877,000.00 TWD. Current Liabilities of CHO Pharma was 2024 110.87 M TWD. It decreases by -99.21% lower compared to the previous year.

The CHO Pharma Current Liabilities history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Current Liabilities
Date
Current Liabilities
Jan 1, 2018
62.54 M TWD
Jan 1, 2019
260.08 M TWD
Jan 1, 2020
292.16 M TWD
Jan 1, 2021
260.13 M TWD
Jan 1, 2022
331.44 M TWD
Jan 1, 2023
205.46 M TWD
Jan 1, 2024
110.87 M TWD
Jan 1, 2025
877,000.00 TWD
The CHO Pharma Current Liabilities history
YEARCurrent LiabilitiesYoY
877,000.00TWD-99.21%
110.87 MTWD-46.04%
205.46 MTWD-38.01%
331.44 MTWD+27.41%
260.13 MTWD-10.96%
292.16 MTWD+12.33%
260.08 MTWD+315.90%
62.54 MTWD+96.90%
31.76 MTWD-12.20%
36.17 MTWD+186.10%
12.64 MTWD-7.60%
13.68 MTWD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

CHO Pharma Stock analysis

What does CHO Pharma do? CHO Pharma, Inc. develops and commercializes innovative biopharmaceutical products using proprietary glycan engineering technologies. The company focuses on eight technology categories: homogeneous antibody drugs, monoclonal antibodies for cancers and immune-related diseases, carbohydrate-related vaccines and drugs, anti-influenza drugs, Saccharin tablets, sugar probes, sugar molecular synthesis and identification, and derivative patents of innovation development plans. These products are targeted at medical and pharmaceutical markets requiring advanced therapeutic solutions. The company's revenue streams come from the development and commercialization of these specialized biopharmaceutical products. Its primary customers are healthcare providers, hospitals, and pharmaceutical distributors seeking advanced treatments for cancer, immune disorders, and infectious diseases. The company's technology segments include antibody therapies, vaccine development, and antiviral drug applications, all leveraging its glycan engineering platform. CHO Pharma's business model centers on leveraging its patented glycan engineering technologies to create and sell high-value pharmaceutical products. The company's product portfolio spans multiple therapeutic areas, including oncology, immunology, and virology, with a focus on developing innovative treatments that address unmet medical needs. Its commercialization strategy involves direct sales to healthcare institutions and partnerships with pharmaceutical distributors for broader market reach. CHO Pharma is one of the most popular companies on Eulerpool.

Frequently Asked Questions about CHO Pharma stock

Current Liabilities of CHO Pharma is 877,000.00 TWD in 2025.

Current Liabilities of CHO Pharma changed from 110.87 M TWD to 877,000.00 TWD, representing a -99.21% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Current Liabilities CHO Pharma since 2006 – with annual values, charts, and detailed analysis.

Current liabilities are obligations due within one year, including accounts payable, short-term debt, and accrued expenses.

Current Liabilities's TWD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Current Liabilities's CHO Pharma historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — CHO Pharma

All Key Metrics — CHO Pharma